Clinical Trial Researching Immunotherapy for Solid Tumors
August 23, 2024
August 23, 2024
BETHESDA, Maryland, Aug. 23 (TNSres) -- The National Institutes of Health's Center for Cancer Research issued the following news:
CCR researchers are studying NEO-201, a monoclonal antibody, in combination with pembrolizumab to see if it is effective against solid tumors, which are abnormal masses of tissue. A clinical trial led by Kevin C. Conlon, M.D., Associate Research Physician in the Women's Malignancies Branch, is researching immunotherapy for solid tumors, including non-smal . . .
CCR researchers are studying NEO-201, a monoclonal antibody, in combination with pembrolizumab to see if it is effective against solid tumors, which are abnormal masses of tissue. A clinical trial led by Kevin C. Conlon, M.D., Associate Research Physician in the Women's Malignancies Branch, is researching immunotherapy for solid tumors, including non-smal . . .